Bristol Myers Squibb stock trades at 56.23 euros after AI deal
Published on 11/06/2026 at 16:52 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWSAI Adds A Pipeline Angle
- Bristol Myers Squibb is combining Pathos Foundry with Tempus patient data for Alzheimer’s and other neuroscience programs.
- BMS leads Pathos AI’s 237 million US dollar Series E financing and secured three-year exclusive neuroscience rights.
- Clinical readouts and regulatory milestones remain the more direct drivers of future earnings expectations.
Bristol Myers Squibb is adding an artificial-intelligence and patient-data angle to its neuroscience pipeline after a collaboration with Pathos AI and Tempus. The companies announced the arrangement on October 23, 2026, according to Tempus.
What Has Changed Since The Last Report
Bristol Myers Squibb stock traded at 56.23 euros on Lang & Schwarz at 16:38 CET on Friday, November 6, 2026. That was 2.60 percent below the 57.73 euros recorded in the previous report on Thursday, November 5, at 12:43 CET. The comparison is measured against that earlier report, not against a Xetra closing price.
The strategic update gives BMS access to Pathos Foundry across its broader research and development portfolio, while the company receives three-year exclusive rights for neuroscience development programs. Tempus plans to build a de-identified longitudinal dataset covering hundreds of thousands of patients with neurological conditions.
AI Supports Drug Development
Pathos will license the dataset from Tempus under a five-year agreement worth 55 million US dollars. Its Foundry platform is intended to examine disease biology, test research hypotheses and help shape more targeted, adaptive clinical trials.
BMS is also leading Pathos AI’s 237 million US dollar Series E financing. The funding is designed to expand Foundry and advance Pathos’s clinical-stage pipeline, including the oncology asset JSKN016. For Bristol Myers Squibb, the commercial payoff depends on whether the collaboration improves candidate selection, patient identification or trial execution.
The real-time quote of Bristol Myers Squibb stock is available alongside further market information.
Bristol Myers Squibb Company Facts
- Company: Bristol Myers Squibb
- ISIN: US1101221083
- Ticker: BMY
- Home market: United States
- Lang & Schwarz quote: 56.23 euros at 16:38 CET, November 6, 2026
- Strategic financing: 237 million US dollars Pathos Series E, led by BMS
- Neuroscience rights: Three-year exclusive access to Pathos Foundry
The S&P 500 is the relevant market backdrop as investors weigh pharmaceutical pipeline productivity against patent and development risks.
More news and analyses on Bristol Myers Squibb stock cover the company’s pipeline and strategic developments.
